Manne Munikumar

Dr. Manne Munikumar

Data manager
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VRVarikasuvu Seshadri Reddy
Varikasuvu Seshadri Reddy
SVSaurabh Varshney
Saurabh Varshney
NDNaveen Dutt
Naveen Dutt
MMManne Munikumar
Manne Munikumar
SAShahir Asfahan
Shahir Asfahan
PGPratima Gupta
Pratima Gupta
Hypercoagulability and the need for prioritizing coagulation markers for prognostic abilities have been highlighted in COVID-19. We aimed to quantify the associations of D-dimer with disease progression in patients with COVID-19. This systematic review and meta-analysis was registered with PROSPERO, CRD42020186661.We included 113 studies in our systematic review, of which 100 records (n = 38,310) with D-dimer data) were considered for meta-analysis. Across 68 unadjusted (n = 26,960) and 39 adjusted studies (n = 15,653) reporting initial D-dimer, a significant association was found in patients with higher D-dimer for the risk of overall disease progression (unadjusted odds ratio (uOR) 3.15; adjusted odds ratio (aOR) 1.64). The time-to-event outcomes were pooled across 19 unadjusted (n = 9743) and 21 adjusted studies (n = 13,287); a strong association was found in patients with higher D-dimers for the risk of overall disease progression (unadjusted hazard ratio (uHR) 1.41; adjusted hazard ratio (aHR) 1.10). The prognostic use of higher D-dimer was found to be promising for predicting overall disease progression (studies 68, area under curve 0.75) in COVID-19. Our study showed that higher D-dimer levels provide prognostic information useful for clinicians to early assess COVID-19 patients at risk for disease progression and mortality outcomes. This study, recommends rapid assessment of D-dimer for predicting adverse outcomes in COVID-19.

31 August 2018 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
VRVarikasuvu Seshadri Reddy
Varikasuvu Seshadri Reddy
SVSatya Prasad V
Satya Prasad V
JKJyothinath Kothapalli
Jyothinath Kothapalli
MMManne Munikumar
Manne Munikumar

3 February 2022 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
VRVarikasuvu Seshadri Reddy
Varikasuvu Seshadri Reddy
BTBalachandar Thangappazham
Balachandar Thangappazham
AVAlekya Vykunta
Alekya Vykunta
PDPragathi Duggina
Pragathi Duggina
MMManne Munikumar
Manne Munikumar
SASowjanya Aloori
Sowjanya Aloori
Vitamin D levels have been reported to be associated with COVID-19 susceptibility, severity and mortality events. We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the...

22 June 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
VNVankudavath Raju Naik
Vankudavath Raju Naik
MMManne Munikumar
Manne Munikumar
URUngarala Ramakrishna
Ungarala Ramakrishna
MSMedithi Srujana
Medithi Srujana
GGGiridhar Goudar
Giridhar Goudar
RHRajkumar Hemalatha
Rajkumar Hemalatha
2019 – Novel Coronavirus (2019-nCOV), enclosed large genome positive-sense RNA virus characterized by crown-like spikes that protrude from their surface, and have a distinctive replication strategy. The 2019-nCOV belongs to the Coronaviridae family, principally consists of virulent pathogens showing zoonotic property, has emerged as a pandemic outbreak with high mortality and high morbidity rate around the globe and no therapeutic vaccine or drugs against 2019-nCoV are discovered till now. In this study, in silico methods and algorithms were used for sequence, structure analysis and molecular docking on Mpro of 2019-nCOV. The co-crystal structure of 2019-nCOV protease, 6LU7 have ∼99% identity with SARS-CoV protease. The 6LU7 residues, Cys145 and His164 are playing a significant role in replication and are essential for the survival of 2019-nCOV. Alongside, 2019-nCOV Mpro sequence is non-homologous to human host-pathogen. Complete genome sequence analysis, structural and molecular docking results revealed that Remdesivir is having a better binding affinity with -8.2 kcal/mol than the rest of protease inhibitors, and peptide. Remdesivir is strongly forming h-bonds with crucial Mpro residues, Cys145, and His164. Further, MD simulation analysis also confirmed, that these residues are forming H-bond with Remdesivir during 100 ns simulations run and found stable (∼99%) by RMSD and RMSF. Thus, present in silico study at molecular approaches suggest that, Remdesivir is a potent therapeutic inhibitor against 2019-nCoV. Communicated by Ramaswamy H. Sarma

1 January 2022 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
MMManne Munikumar
Manne Munikumar
VRVankudavath Naik Raju
Vankudavath Naik Raju
PDParasannanavar Devaraj
Parasannanavar Devaraj
NBNaveen Kumar Boiroju
Naveen Kumar Boiroju
KDK.S. Dhiman
K.S. Dhiman
Outbreak of Corona Virus Disease in late 2019 (COVID-19) has become a pandemic global Public health emergency. Since there is no approved anti-viral drug or vaccine declared for the disease and investigating existing drugs against the COVID-19. AYUSH-64 is an Ayurvedic formulation, developed and patented by Central Council of Research in Ayurvedic Sciences, India, has been in clinical use as anti-malarial, anti-inflammatory, anti-pyretic drug for few decades. Thus, the present study was undertaken to evaluate AYUSH-64 compounds available in this drug against Severe Acute Respiratory Syndrome-Corona Virus (SARS-CoV-2) Main Protease (Mpro; PDB ID: 6LU7) via in silico techniques. Different molecular docking software’s of Discovery studio and Auto Dock Vina were used for drugs from selected AYUSH-64 compounds against SARS-CoV-2. We also conducted 100 ns period of molecular dynamics simulations with Desmond and further MM/GBSA for the best complex of AYUSH-64 with Mpro of SARS-CoV-2. Among 36 compounds of four ingredients of AYUSH-64 screened, 35 observed to exhibits good binding energies than the published positive co-crystal compound of N3 pepetide. The best affinity and interactions of Akuammicine N-Oxide (from Alstonia scholaris) towards the Mpro with binding energy (AutoDock Vina) of -8.4 kcal/mol and Discovery studio of Libdock score of 147.92 kcal/mol. Further, molecular dynamics simulations with MM-GBSA were also performed for Mpro– Akuammicine N-Oxide docked complex to identify the stability, specific interaction between the enzyme and the ligand. Akuammicine N-Oxide is strongly formed h-bonds with crucial Mpro residues, Cys145, and His164. The results provide lead that, the presence of Mpro– Akuammicine N-Oxide with highest Mpro binding energy along with other 34 chemical compounds having similar activity as part of AYUSH-64 make it a suitable candidate for repurposing to management of COVID-19 by further validating through experimental, clinical studies.

5 February 2013 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
DPDibyabhaba Pradhan
Dibyabhaba Pradhan
VPVani Priyadarshini
Vani Priyadarshini
MMManne Munikumar
Manne Munikumar
SSSandeep Swargam
Sandeep Swargam
AUAmineni Umamaheswari
Amineni Umamaheswari
ABAparna Bitla
Aparna Bitla
Leptospira interrogans, a Gram-negative bacterial pathogen is the main cause of human leptospirosis. Lipid A is a highly immunoreactive endotoxic center of lipopolysaccharide (LPS) that anchors LPS into the outer membrane of Leptospira. Discovery of compounds inhibiting lipid-A biosynthetic pathway would be promising for dissolving the structural integrity of membrane leading to cell lysis and death of Leptospira. LpxC, a unique enzyme of lipid-A biosynthetic pathway was identified as common drug target of Leptospira. Herein, homology modeling, docking, and molecular dynamics (MD) simulations were employed to discover potential inhibitors of LpxC. A reliable tertiary structure of LpxC in complex with inhibitor BB-78485 was constructed in Modeller 9v8. A data-set of BB-78485 structural analogs were docked with LpxC in Maestro v9.2 virtual screening workflow, which implements three stage Glide docking protocol. Twelve lead molecules with better XP Gscore compared to BB-78485 were proposed as potential inhibitors of LpxC. Para-(benzoyl)-phenylalanine – that showed lowest XP Gscore (−10.35 kcal/mol) – was predicted to have best binding affinity towards LpxC. MD simulations were performed for LpxC and para-(benzoyl)-phenylalanine docking complex in Desmond v3.0. Trajectory analysis showed the docking complex and inter-molecular interactions was stable throughout the entire production part of MD simulations. The results indicate para-(benzoyl)-phenylalanine as a potent drug molecule against leptospirosis. An animated Interactive 3D Complement (I3DC) is available in Proteopedia at http://proteopedia.org/w/Journal:JBSD:10